89. Lymphangioleiomyomatosis Clinical trials / Disease details


Clinical trials : 39 Drugs : 46 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 137

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03062943
(ClinicalTrials.gov)
October 20167/10/2016A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)LymphangioleiomyomatosisDrug: NintedanibIRCCS MultimedicaNULLRecruiting18 YearsN/AFemale30Phase 2Italy
2EUCTR2015-004919-20-IT
(EUCTR)
09/03/201611/08/2016A pilot study of nintedanib for lymphangioleiomyomatosis (LAM)A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) - A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) Female subjects affected by Llymphangioleiomyomatosis (LAM)
MedDRA version: 19.0;Level: PT;Classification code 10049459;Term: Lymphangioleiomyomatosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: OfevMULTIMEDICA S.P.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
30Phase 3Italy